Aptevo Therapeutics announced an 87% clinical benefit rate for mipletamig in frontline AML, alongside securing a $1.5 million grant to advance its trispecific candidate APVO451. The strong clinical data and funding enhance Aptevo’s potential for future growth.

Key Highlights

  • Mipletamig shows an 87% clinical benefit rate in frontline acute myeloid leukemia patients.
  • Newly appointed Chief Scientific Officer Mary J. Janatpour brings over 25 years of experience to advance Aptevo’s oncology pipeline.
  • Mipletamig remains central to Aptevo's strategy, with updated data from the Phase 1b/2 RAINIER trial indicating strong activity in frontline AML.

Aptevo Therapeutics Inc. (NASDAQ: APVO) reported compelling clinical data for its lead candidate mipletamig, demonstrating an 87% clinical benefit rate among frontline acute myeloid leukemia (AML) patients. The performance highlights mipletamig's potential effectiveness when combined with existing treatments, reinforcing Aptevo's strategic focus on improving outcomes for patients with significant unmet medical needs. The company raised $0.6 million through Standby Equity Purchase Agreements during the second quarter, strengthening its financial position with $9.8 million in cash and equivalents as of June 30, 2026, setting the stage for continued Investment in innovation.

Mipletamig's Strong Performance in AML

Mipletamig remains central to Aptevo's strategy, with updated data from the Phase 1b/2 RAINIER trial indicating strong activity in frontline AML. The clinical findings show that 87% of evaluable patients benefited from the treatment and an impressive 81% achieved remission. Among those who reached complete remission or complete remission with incomplete blood count recovery (CR/CRi), 55% attained measurable residual disease-negative levels, suggesting durable responses.

The results have positioned Aptevo to finalize dose optimization by the end of the year, with a planned regulatory interaction for Phase 2 expected early in 2027. This advancement illustrates mipletamig's potential applicability across broader AML populations, essential for making strides in treating this challenging condition.

Grant Funding Validates Strategic Initiatives

This grant not only adds third-party validation for the viability of APVO451 but also underscores Aptevo’s capability in advancing its innovative oncology programs efficiently. The selection of a development candidate for APVO451 is targeted for year-end 2026, with IND-enabling studies scheduled to commence in the first quarter of 2027. Successful advancement in the trispecific solid tumor strategy could serve as a key driver of Aptevo's future portfolio growth, bolstering its therapeutic offerings.

Leadership Addition Enhances Pipeline Execution

Mary J. Janatpour, Ph.D. Has been appointed Senior Vice President and Chief Scientific Officer at Aptevo, bringing over 25 years of experience in oncology research and development. Her Leadership is expected to strengthen the execution of Aptevo’s clinical and preclinical priorities while advancing the company’s expanding oncology pipeline. Janatpour's extensive background positions her to lead the development of existing and future programs, including the new collaboration with Niowave focused on radiopharmaceutical therapeutics.

This expansion into radiopharmaceuticals and the strategic alignment with Niowave enhance Aptevo's capability to compete in a rapidly evolving oncology environment.

Strategic Collaboration Expands Development Opportunities

This Partnership reflects a strategic move into a promising sector within oncology, capitalizing on increasing interest from big pharmaceutical players. By sharing development costs and leveraging Niowave's radioisotope production capabilities, Aptevo positions itself effectively in an area marked by a shortage of isotopes. The collaboration also includes an equity investment from Niowave, which provides Aptevo with an initial 7.9% ownership stake that could increase to 19.99%.

This collaborative approach could facilitate innovative therapeutic development while enhancing Shareholder value as the market for radiopharmaceuticals grows.

Peers Moving on This News